SAN FRANCISCO, May 15, 2019 /PRNewswire-PRWeb/ -- Slone Partners, North America's leading executive search firm for life sciences and diagnostics companies, announces the placement of Richard Wenstrup, M.D., at Epic Sciences, Inc. as Chief Medical Officer. Dr. Wenstrup leads clinical development, regulatory and medical affairs strategies, and is responsible for advancing the company's clinical research and product development pipeline. Based at the company's headquarters in San Diego, California, he reports directly to CEO Lloyd Sanders.
Epic Sciences develops novel diagnostics to improve and personalize the treatment and management of cancer with a mission to extend patient lives. The company's goal is to offer greater clarity for doctors to make correct decisions for patients at pivotal points in treating that cancer, and to rapidly pivot away from therapies that are no longer clinically effective. Currently working with 65 top pharmaceutical partners and 45 academic cancer hospitals, including the National Cancer Institute, Epic Sciences' technology is being used in over 200 clinical trials and has tested over 80,000 patient samples. Utilizing this rare-cell detection engine technology, the company has the world's leading pipeline of personalized, predictive and proven tests to guide therapy selection across the most impactful drug classes in oncology. For example, Epic Sciences has partnered with Genomic Health to commercialize the first predictive liquid biopsy test for prostate cancer. The company is building a strong pipeline of additional tests for other cancer indications.
Dr. Wenstrup has 25 years of clinical leadership experience in oncology, genetics and pharmacogenomics. Previously, he served as Chief Medical Officer for Oxford Immunotec, Inc., where he oversaw research and development, product development, regulatory, and medical & clinical affairs. From 2006-2017, Dr. Wenstrup served as Chief Medical Officer for Myriad Genetics, Inc. where he built and led the clinical and medical affairs team to support a multi-fold increase in revenue during his tenure. He was actively involved in the company's product development, M&A and in-licensing activities. As an entrepreneur, Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc. Before joining industry, he served as a tenured Professor of Pediatrics in Human Genetics at Cincinnati Children's Hospital Medical Center, and as a tenured Professor of Biomedical Engineering at the University of Cincinnati, where he earned his medical degree.
Says Slone Partners President Tara Kochis-Stach, "Dr. Wenstrup's decades-long experience in oncology leadership and clinical work will add substantial value to Epic Sciences in developing exciting new diagnostic tests that advance the mission of precision medicine."
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing scientific healthcare organizations – People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT EPIC SCIENCES
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego. Further information is available on the Company's website http://www.epicsciences.com.
SOURCE Slone Partners
Share this article